TLSI Investigation Alert: Levi & Korsinsky Takes Action!

TriSalus Life Sciences, Inc. (NASDAQ: TLSI) – an oncology-focused medical technology company – is under the spotlight after a sharp guidance cut triggered a shareholder investigation by law firm Levi & Korsinsky (www.prnewswire.com). This report examines TriSalus’s financial profile and outlook, including its dividend policy, leverage, valuation, and the risks/red flags highlighted by recent events. All information is grounded in first-party filings and credible sources, with inline citations for verification.

Company Overview

TriSalus Life Sciences went public via a SPAC merger in August 2023, combining with MedTech Acquisition Corp (www.sec.gov). The Colorado-based company provides a drug-delivery device platform (TriNav® for Pressure-Enabled Drug Delivery, or PEDD) used in treating liver and pancreatic tumors, and it is developing an immunotherapy (SD-101) for solid tumors (investors.trisaluslifesci.com). TriSalus has been growing revenue rapidly – full-year 2025 revenue was about $45.2 million, up 53% year-over-year, exceeding its own guidance for that year (investors.trisaluslifesci.com). Entering 2026, management initially guided for $60–$62 million in 2026 revenue (investors.trisaluslifesci.com), reflecting optimism about continued growth.

However, first-quarter 2026 results showed revenue of $8.9 million, slightly below the $9.4 million consensus and even down ~2.9% from the $9.2 million in Q1 2025 (ca.investing.com) (ca.investing.com). The company attributed the Q1 revenue dip to ramp-up of its expanded commercial organization (i.e. short-term growing pains in sales efforts) (ca.investing.com). Despite trailing twelve-month revenue growth of 53%, the weaker Q1 and other developments forced TriSalus to slash its full-year 2026 guidance to $54–$57 million, roughly a 13% cut from the prior midpoint (www.prnewswire.com). This reversal – reaffirming $60–$62M guidance as recently as March 5, 2026, then lowering it by May – led to a sharp loss of investor confidence. On the trading day after the guidance cut, TLSI’s stock price plunged about 41%, falling from the mid-$4 range to around $2.66 per share (stockanalysis.com). Year-to-date, the stock had already been under pressure (down ~35% YTD to $4.57 just before the Q1 miss) (ca.investing.com). The post-guidance-cut collapse has now put TriSalus’s market capitalization near the ~$150–$170 million level, roughly 3× forward sales (using the new outlook), down from about 6× sales before (stockanalysis.com). In short, TriSalus is a high-growth but still unprofitable med-tech company whose credibility has been dented by recent execution issues.

Dividend Policy & History

TriSalus does not pay any dividend on its common stock, nor has it paid one historically (content-archive.fast-edgar.com). This is typical for a development-stage healthcare company – all available capital is retained to fund expansion, R&D, and operations rather than distributed to shareholders (content-archive.fast-edgar.com). Management has stated an intent to retain all earnings for reinvestment and currently has no plans to initiate cash dividends in the foreseeable future (content-archive.fast-edgar.com) (content-archive.fast-edgar.com). Given TriSalus’s net losses (–$69.7 million net loss in 2025) (stockanalysis.com) and need to invest in commercial and clinical growth, a 0% dividend yield is expected to persist. Investors in TLSI are thus focusing on capital gains potential rather than income, and any future consideration of dividends would depend on the company reaching sustained profitability and meeting its capital requirements.

(AFFO/FFO measures are not applicable to TriSalus, as these metrics are used for REITs or cash-flowing real estate businesses. TriSalus’s performance is better gauged by revenue growth, gross margins, and operating cash flow rather than funds-from-operations.)

Leverage and Debt Maturities

Leverage: Despite being early in its commercial stage, TriSalus carries a significant debt load for a small-cap company. As of March 31, 2026, the company had about $33 million in long-term debt on its balance sheet (www.sec.gov). This debt stems from a credit facility with OrbiMed (a healthcare-focused investment firm) that was put in place to fund growth. The OrbiMed loan is structured atypically: it includes revenue-based repayment provisions. Specifically, if TriSalus’s product revenues don’t reach certain thresholds by set test dates, the company must begin repaying the loan principal in monthly installments before final maturity (www.streetinsider.com) (www.streetinsider.com). The loan’s maturity date is April 30, 2029, and any remaining principal is due at that time (www.streetinsider.com). Notably, repayments (when triggered) come with hefty premiums and an exit fee, which effectively increase the cost of the debt (www.streetinsider.com). This structure – recorded partly as a “Revenue Base Redemption Liability” on the balance sheet – aligns the lender’s returns with TriSalus’s sales performance and cash generation (www.streetinsider.com).

The interest rate on the debt is relatively high: TriSalus recorded $1.44 million of interest expense in Q1 2026 alone (www.sec.gov). Annualizing that suggests an effective interest rate well into the teens as a percentage of principal, reflecting the risk profile of the loan. Such interest costs are a burden given the company’s negative operating income; currently, interest is being serviced out of cash rather than profits.

Liquidity: To shore up its finances, TriSalus raised equity capital in early 2026. The company completed a $46 million equity raise during Q1 2026, boosting its quarter-end cash balance to $56.6 million (www.sec.gov). This cash injection – likely via a stock issuance under a standby equity purchase agreement or private placement – “strengthened the balance sheet” and, according to management, fully funds the planned commercial expansion and pipeline development initiatives (www.sec.gov). For context, TriSalus had only ~$20.4 million in cash at year-end 2025 (investors.trisaluslifesci.com), so the new financing was critical to extend its runway. The company also has access to committed equity financing: it entered a Standby Equity Purchase Agreement (SEPA) with an investor (Yorkville Advisors), enabling TriSalus to sell additional shares up to a limit (~5.26 million shares, or 19.99% of outstanding) as needed (www.streetinsider.com). This facility provides flexibility to raise cash quickly, though at the cost of diluting existing shareholders if utilized.

Maturities: With the OrbiMed term loan not due until 2029, TriSalus faces no near-term debt maturities. The principal repayments will only accelerate if revenue hurdles are missed; otherwise, mandatory repayment could be back-loaded toward 2028–2029 (www.streetinsider.com). This long-dated debt maturity schedule gives management some breathing room to grow the business before heavy debt servicing kicks in. Nonetheless, investors should monitor those revenue “test dates” closely – underperformance on sales could trigger earlier payment obligations (plus premiums) that would pressure cash flow (www.streetinsider.com) (www.streetinsider.com). Aside from the OrbiMed loan, other liabilities include lease obligations and contingent liabilities from the SPAC merger: e.g. a contingent earnout payable in shares if certain milestones are met (fair-valued at ~$2.7 million as of Q1 2026, down from $10 million at year-end 2025) (www.sec.gov). The drop in the earnout liability reflects reduced likelihood of hitting the stock price or revenue targets required, but if TriSalus’s fortunes improve, issuance of those earnout shares could dilute shareholders. Similarly, public warrants from the SPAC remain outstanding (expiring in 2028) (www.streetinsider.com) – these would allow warrant-holders to purchase common shares (at $11.50 exercise) if the stock price rises sufficiently, potentially adding to shares outstanding (www.streetinsider.com). In summary, TriSalus’s capital structure includes debt, warrants, and contingent equity, which together create leverage and potential dilution that investors must weigh.

Coverage and Cash Flow

Given its negative earnings, TriSalus’s interest coverage is currently insufficient by traditional measures. The company is operating at a loss (–$69.7M net loss in 2025) (stockanalysis.com), so EBIT is well below zero. Even on an adjusted EBITDA basis, the company is likely deeply negative once R&D and SG&A are accounted for. With quarterly interest expense of ~$1.4M (www.sec.gov), TriSalus has no operating profit to cover these fixed charges – effectively, coverage ratios are not meaningful at this stage. Instead, debt service is being supported by the cash reserves from financing activities. On a revenue basis, quarterly interest (~$1.4M) was 16% of Q1’s $8.9M sales – a high burden, especially as operating expenses far exceed gross profit. This underscores that TriSalus must continue to burn cash to fuel operations and service debt, until it can scale to breakeven.

Positively, the $56.6M cash on hand provides some runway. Management has asserted this is enough to fund current growth initiatives (e.g. hiring sales reps, launching new products, and progressing clinical trials) (www.sec.gov). In practice, whether the cash is sufficient will depend on the trajectory of revenues and expenses. In Q1 2026, net cash used in operating activities and investing was partially offset by the $42M net financing inflow (www.sec.gov); without further raises, the existing cash could potentially support a few more quarters of operations at the current burn rate. Investors should watch free cash flow and the quarterly cash burn relative to the remaining cash. If sales ramp up toward the revised guidance, the burn may moderate via higher gross profits; if not, TriSalus might need to tap additional equity (e.g. the SEPA) or debt well before 2029. In short, coverage of obligations right now relies on external capital, and achieving self-sufficiency remains a longer-term goal.

Valuation Profile

Traditional valuation metrics are challenging to apply to TriSalus due to its lack of earnings and early-stage growth profile. The company’s Price-to-Earnings (P/E) is not meaningful (negative earnings), and cash-flow based metrics are also negative. Analysts and investors instead look at revenue multiples and the growth outlook. Prior to the recent sell-off, TriSalus was valued at roughly 6× trailing revenue (market cap ~$272M vs. ~$45M TTM sales) (stockanalysis.com), reflecting high growth expectations. The stock’s plunge to ~$2.50–$3 has cut that multiple roughly in half – at a ~$160M market cap, the enterprise value is around $140M (net of cash and debt, given $33M debt and $56M cash), which equates to about 2.5–3.0× the new 2026 revenue forecast (~$55M). For an oncology med-tech company with ~50% annual growth (historically) but ongoing losses, a mid-single-digit P/S ratio is not unusual, though now TriSalus is at the lower end of that range after the disappointment.

It’s worth noting that TriSalus’s valuation also hinges on its pipeline upside. The current revenues come from TriNav® device sales, but the company’s future could be materially impacted by its investigational therapy SD-101 and next-gen devices. Any clinical breakthrough (or setback) could swing the stock significantly beyond what revenue multiples imply. Comparably, healthcare device firms with similar revenue scale but slower growth (and profits) might trade at lower multiples (2–4× sales), whereas high-growth med-tech or biotech firms often trade higher if investors anticipate steep revenue acceleration or eventual margin expansion. In TriSalus’s case, the market appears to be re-rating the stock’s risk after management tempered its outlook. Until the company restores confidence, its valuation may remain constrained. No Wall Street analyst coverage has been widely reported (this is a small-cap name), but prospective investors can benchmark TriSalus against other emerging oncology device players. Ultimately, the upside in TLSI’s valuation will depend on it hitting growth milestones (to justify a richer multiple) and charting a path toward profitability (to eventually enable P/E or EV/EBITDA analysis).

Risks, Red Flags, and Controversies

Several risks and red flags have become apparent in the TriSalus story, especially after the recent developments:

– Credibility of Guidance: The most immediate red flag is the company’s revenue guidance U-turn. On March 5, 2026, CEO Mary Szela publicly reaffirmed the $60–$62M 2026 revenue guidance during the Q4 earnings call (www.prnewswire.com). Barely two months later, TriSalus cut that outlook by ~$8 million (13%) due to lower-than-expected Q1 sales and timing issues with a new product launch (www.prnewswire.com). During the interim, management had not signaled any softness, which means the cut came as a negative surprise. The share price collapse (–41% in one day) (stockanalysis.com) indicates investors felt blindsided. This raises concern that either the initial guidance was too aggressive or that management failed to promptly disclose deteriorating trends. Levi & Korsinsky’s investigation is probing “whether TriSalus made materially false or misleading statements regarding its 2026 revenue outlook and commercial demand trends” (www.prnewswire.com). In other words, did management know (or should they have known) that the original target was unachievable, but kept promoting it? The outcome of this inquiry could lead to shareholder lawsuits, and regardless, it has eroded trust in management’s communication. Going forward, any guidance or forward-looking statements from TriSalus may be met with investor skepticism – the company will need to rebuild credibility through consistent execution.

– Operational and Execution Risks: TriSalus is still in the early stages of commercializing its PEDD device technology. The Q1 revenue slip underscores operational risk – for example, expanding the sales force disrupted short-term sales momentum (ca.investing.com). There’s a risk that adoption of TriNav could be slower than anticipated, or that training new sales reps and interventional radiologists takes more time, affecting revenues. Moreover, regulatory timing risk has already materialized: the revision to guidance was partly due to the “timing of FDA clearance for TriNav® Advance”, the next-generation device (www.sec.gov). Any delay in regulatory approvals (for TriNav Advance or the SD-101 drug trials) can push revenue or milestone timelines out. TriSalus operates in a competitive and innovation-driven niche – if a competitor introduces a superior liver tumor delivery system or therapy, it could curtail TriSalus’s market opportunity. Additionally, as a small company, TriSalus depends heavily on key personnel (e.g. its scientific and commercial leaders) – execution missteps or talent losses could impair its progress.

– Financial and Dilution Risk: TriSalus’s financial sustainability is a major concern. The company is burning cash and will likely need to raise additional capital until it reaches positive cash flow. Even after the recent $46M raise, the cash runway may only cover a limited period (perhaps through 2026, depending on cash burn). If performance lags, dilutive equity raises could occur sooner and at unfavorable prices. The company has openly warned that future financings or offerings could dilute existing shareholders and pressure the stock price (content-archive.fast-edgar.com). Indeed, TriSalus has mechanisms in place (like the Yorkville equity facility) to issue more shares as needed (www.streetinsider.com). The overhang of warrants and convertible securities from the SPAC deal is another source of potential dilution – for instance, if the stock recovers above $11.50, over a million public warrants could be exercised into common shares (www.streetinsider.com). All these factors mean that current shareholders face the risk of their ownership being diluted as the company finances its growth. On the debt side, the high-interest OrbiMed loan amplifies financial risk – not only does it incur steep interest (which deepens operating losses), but if revenues fall short of thresholds, TriSalus might have to allocate cash to debt repayments earlier than planned (www.streetinsider.com). This “leverage” could become a strain if the business doesn’t scale fast enough. In a distress scenario, OrbiMed could potentially accelerate the loan on an event of default (www.streetinsider.com), though to date the lender has not exercised any default rights.

– Litigation and Governance: The Levi & Korsinsky action highlights legal risk. If evidence emerges that TriSalus’s officers misled investors, the company could face a class-action lawsuit or SEC inquiry. Even if lawsuits are eventually settled, they carry reputational damage and distraction for management, not to mention potential financial costs (settlements or higher D&O insurance premiums). At this stage it’s only an investigation – no lawsuit has been filed yet – but often such probes precede class actions if stockholder losses are significant. Beyond this incident, investors should be mindful of general governance on small-cap SPAC-derived companies: TriSalus has an insider ownership structure that included venture backers and SPAC sponsors, and it underwent complex financing (preferred stock, earnouts, etc.) (content-archive.fast-edgar.com) (content-archive.fast-edgar.com). While there’s no specific allegation beyond the guidance issue, the SPAC history can present governance quirks — for example, warrants or preferred shares that benefit certain holders, or optimistic business projections made during the de-SPAC process that didn’t pan out. So far, TriSalus’s board and management have not been accused of anything beyond this guidance matter, but it’s a situation to monitor. The fact that a Top-50 securities litigation firm is looking into the company suggests that shareholders with losses are voicing discontent (www.prnewswire.com).

In summary, TriSalus faces a multifaceted risk environment: execution risk in selling and developing its therapies, financial risk from high cash burn and leverage, and now a credibility risk in the eyes of investors. The next few quarters will be pivotal for the company to demonstrate that Q1 was a hiccup rather than a trend, and to show that it can meet (or beat) the revised targets without further surprises.

Open Questions and What to Watch

Given the uncertainties, here are some open questions and areas for investors to watch going forward:

– **Will TriSalus achieve its revised 2026 revenue guidance? After the reset to $54–$57 million (www.prnewswire.com), the company still needs a substantial acceleration in the remaining quarters to hit that range (roughly $45+ million over Q2–Q4 vs. $8.9M in Q1). Can the expanded salesforce and upcoming product launch drive the roughly 20%+ sequential growth per quarter that may be required, or is even the lowered guidance at risk?

– When will the FDA clear TriNav® Advance, and how will its launch impact sales? Management cited the timing of TriNav Advance approval as a reason for the guidance cut (www.sec.gov). If clearance comes later than expected (e.g. late 2026), revenue might be back-loaded or deferred into 2027. Conversely, a timely approval and successful rollout could re-accelerate growth. Investors should watch for regulatory updates and any commentary on initial adoption of the new device once launched.

– How long will the current cash last, and will further capital raises be needed?** With $56.6M in cash at Q1’s end (www.sec.gov) and ongoing losses, it’s crucial to estimate TriSalus’s cash runway. Will the company need to tap the Yorkville equity facility or issue more shares in 2027 to fund operations? Management claims to be fully funded for now (www.sec.gov), but a clearer statement (e.g. “funded through [Quarter X 2027]”) is lacking. Any signs of unexpected cash burn or new financing activities (ATM offerings, debt drawdowns) will be telling.

– What will the Levi & Korsinsky investigation uncover? The central issue is whether TriSalus management knew of adverse trends (in demand or revenue) before cutting guidance and failed to disclose them (www.prnewswire.com). For example, were Q1 sales tracking poorly by late February, and did management still reaffirm guidance in March regardless? If evidence (emails, meeting notes, etc.) shows internal concern about hitting $60M+ while outward optimism continued, it could lead to a formal lawsuit. On the other hand, if the miss was genuinely unforeseen (e.g. a sudden change in hospital purchasing patterns or an unexpected regulatory delay), management might be cleared of misconduct. The resolution of this will influence investor trust and could result in changes like stricter internal controls or even leadership changes if accountability is demanded.

– Can TriSalus move toward profitability before needing more debt? The company’s strategy presumably banks on operating leverage – as revenue grows (and high gross margin device sales increase), losses should shrink. A key question is at what annual revenue level TriSalus could break even on an EBITDA or cash flow basis. If the answer is far above the $60M range (given current expense levels, likely it is), investors will want to see a roadmap: e.g. “we aim to reach cash breakeven at $X million revenue by 202Y.” Any improvement in gross margin or reduction in OpEx growth can indicate progress. If losses remain large relative to revenue, the company might either need to cut costs (potentially slowing R&D) or risk piling on more high-cost debt to bridge the gap.

– How will pipeline developments play into the story? While most of this report focused on the device business, TriSalus’s immunotherapy candidate SD-101 (for uveal melanoma and hepatobiliary tumors) is an important wildcard. It’s currently in clinical trials (investors.trisaluslifesci.com). Positive trial results or partnership deals could materially boost the company’s prospects (and likely require significant funding for Phase 3 trials). Conversely, setbacks in clinical trials would remove a pillar of the long-term growth narrative. Investors should keep an eye on clinical data readouts and any mention of partnering (e.g. co-development with a larger pharma) which could de-risk the program.

– Is the stock oversold or still risky after the drop? Now that TLSI trades around the mid-$2 range, one might ask if the market reaction was overdone or appropriately pricing in risk. At ~3× forward sales, the valuation assumes the company can execute moderately but also reflects doubt. If TriSalus delivers a couple of solid quarters and meets the new guidance, the stock could stabilize or rebound. On the other hand, any further disappointment – another revenue miss, additional guidance revision, regulatory delay, or need for capital – could suppress the stock price further. The balance of risk/reward will depend on near-term execution. New investors considering the stock now will be looking for evidence that the “inflection point” story is still intact, whereas current shareholders will be looking for reassurance that Q1 was an anomaly.

In conclusion, TriSalus Life Sciences faces a critical period of regaining investor confidence. The Levi & Korsinsky investigation has put management’s statements under a microscope, and the company’s financial path requires robust revenue growth to support its ambitions. Stakeholders should closely follow the upcoming earnings calls for any updates on commercial traction (TriNav utilization growth, hospital adoption), pipeline milestones, and management’s tone regarding guidance. While the recent alert is cause for caution, it also serves as an inflection alert – either TriSalus will learn from these stumbles and execute more prudently, or deeper issues could emerge. Investors will be watching for which scenario unfolds, armed with the facts and risks outlined above.

Sources:

– TriSalus Life Sciences – Preliminary Q4 2025 Results & 2026 Guidance (Jan 12, 2026) (investors.trisaluslifesci.com) (investors.trisaluslifesci.com) – TriSalus Life Sciences – Q1 2026 Earnings Release (May 12, 2026) (www.sec.gov) – Levi & Korsinsky, LLP – Shareholder Investigation Press Release (May 15, 2026) (www.prnewswire.com) (www.prnewswire.com) (www.prnewswire.com) – Investing.com/Reuters – Q1 2026 Results News Highlights (ca.investing.com) (ca.investing.com) – StockAnalysis.com – TLSI Stock Data & Financial Metrics (stockanalysis.com) – SEC Form 10-K (2025) – TriSalus Annual Report (content-archive.fast-edgar.com) (content-archive.fast-edgar.com) (content-archive.fast-edgar.com) – SEC Form 10-Q (Q1 2026) – TriSalus Quarterly Report (www.sec.gov) (www.sec.gov) (www.streetinsider.com) (www.streetinsider.com) (www.streetinsider.com) – TriSalus Investor Presentation & SEC filings – Company background and risk disclosures (content-archive.fast-edgar.com) (www.streetinsider.com).

For informational purposes only; not investment advice.